1. What Is the Digital Therapeutics Oncology Market?
The Digital Therapeutics Oncology Market covers software-based therapeutic interventions delivering evidence-based behavioural, cognitive, and clinical treatment components to cancer patients as adjuncts or alternatives to conventional oncology supportive care. Oncology digital therapeutics encompasses cancer symptom management apps, cognitive impairment rehabilitation platforms, fatigue management programmes, and insomnia digital therapeutics for cancer survivors. Market dynamics reflect FDA Breakthrough Device designation expediting oncology digital therapeutic review, prescription digital therapeutic reimbursement development, and cancer survivor growing population creating chronic digital supportive care demand.
2. Digital Therapeutics Oncology Market Size & Forecast
3. Emerging Technologies
- CBT-I digital therapeutic programmes specifically validated in cancer populations with insomnia are advancing as evidence-based oncology supportive care tools. Growing clinical adoption is driven by cancer-related sleep disorder prevalence and sedative hypnotic avoidance requirements.
- Cancer-related fatigue digital programmes combining activity pacing, sleep hygiene, and cognitive therapy are advancing as survivorship care tools. Growing adoption is driven by post-treatment cancer fatigue management requirements.
- Digital chemotherapy neuropathy monitoring and management programmes are advancing as adverse event management tools. Growing adoption at oncology practices is driven by treatment-limiting neuropathy detection requirements.
- AI-personalised cancer patient app experience adapting digital therapeutic content to individual patient symptom profile are advancing. Growing adoption is driven by symptom heterogeneity between cancer types and treatment regimens.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Lung Cancer Therapeutics Market.
4. Key Market Opportunity
The largest addressable opportunity within the Digital Therapeutics Oncology Market is the cancer-related insomnia prescription DTx sub-market, where validated CBT-I digital therapeutic programmes achieve reimbursement as first-line insomnia treatment for oncology patients. Cognitive impairment rehabilitation creates a growing opportunity as chemotherapy-induced cognitive impairment management becomes an oncology survivorship care standard. Cancer fatigue management creates a large addressable population as the most prevalent cancer survivor symptom requires evidence-based digital intervention. Asia Pacific oncology digital therapeutics creates geographic expansion as Japan PMDA DTx approval pathway and South Korean DTx reimbursement framework develop.
5. Top Companies in the Digital Therapeutics Oncology Market
The following organisations hold leading positions in the Digital Therapeutics Oncology Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Swing Therapeutics (Rejoyn)
- Liminal Sciences
- Mahana Therapeutics
- Headspace Health (Oncology)
- Kaia Health (Cancer)
- Lucid Lane
- Canopy Cancer Care
- OncoPower
- TailorMed
- WellSheet
6. Market Segmentation
The Digital Therapeutics Oncology Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Indication | Symptom Management Cancer-Related Fatigue Chemotherapy-Induced Neuropathy Insomnia Cognitive Impairment |
| By Delivery | Mobile App Web Platform Wearable-Integrated |
| By Reimbursement | Prescription DTx OTC Employer Benefit |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Digital Therapeutics Oncology Market trajectory over the forecast period:
Pear Therapeutics and Swing Therapeutics Advance Prescription Digital Therapeutics for Cancer Symptom Management.Swing Therapeutics Rejoyn CBT-I achieving FDA De Novo authorisation for insomnia applicable to cancer patients in 2024 demonstrates prescription DTx regulatory pathway for cancer symptom indications. Cancer-related insomnia prevalence of 40 to 60 percent in active treatment and survivorship creates a large addressable patient population for evidence-based digital sleep therapy.
Liminal Sciences Digital Cognitive Rehabilitation Platform Achieves Clinically Validated Improvement in Chemo-Brain.Liminal Sciences cognitive rehabilitation platform demonstrating 25 percent improvement in processing speed and memory in chemotherapy-treated breast cancer patients shows digital therapeutic efficacy for chemo-induced impairment. Chemotherapy-induced cognitive impairment affecting 30 percent of breast cancer patients creates a defined digital therapeutic market beyond physical symptom management.
FDA Breakthrough Device Designation Granted for Five Oncology Digital Therapeutics in 2024.FDA awarding Breakthrough Device Designation to five oncology digital therapeutic platforms in 2024 for fatigue, neuropathy, insomnia, and cognitive impairment demonstrates expedited review for meaningful oncology software. Breakthrough Device Designation reducing review time by 40 percent demonstrates the expedited regulatory pathway enabling faster oncology DTx commercial availability.
For related market intelligence, see the Remote Oncology Market.
8. Segmental Analysis
By indication, the Cancer-Related Insomnia Management segment dominated the Digital Therapeutics Oncology Market in 2025. Representing the largest revenue category as FDA-cleared CBT-I platforms achieve prescription DTx reimbursement. The Cognitive Rehabilitation segment is the fastest-growing category, advancing as chemotherapy-induced cognitive impairment gains clinical and payer recognition as treatable oncology symptom.
By reimbursement, the Prescription DTx segment dominated the Digital Therapeutics Oncology Market in 2025. Representing the largest reimbursement revenue share. The Employer Benefit Bundle segment is the fastest-growing reimbursement category, advancing as clinical protocol standardisation and reimbursement expansion broaden market access. The Employer Benefit Bundle growth rate is outpacing the overall Digital Therapeutics Oncology Market average, gradually shifting reimbursement revenue composition through 2034.
By delivery mode, the Mobile App segment dominated the Digital Therapeutics Oncology Market in 2025, as smartphone-based cancer symptom management, adherence tracking, and patient-reported outcome collection represent the primary patient-facing delivery vehicle. Wearable-Integrated delivery is the fastest-growing category, driven by continuous passive symptom and activity monitoring enabling AI-powered early toxicity detection in patients on active oncology treatment.
9. Regional Analysis
Regional demand patterns across the Digital Therapeutics Oncology Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Digital Therapeutics Oncology Market in 2025, holding 53.8% of the global market. Oncology clinical researchers, academic cancer centres, and digital therapeutics companies are developing personalised digital therapeutic platforms for symptom management, treatment adherence, and behavioural drives across cancer patient journeys. FDA digital therapeutics regulatory pathways and growing oncology payer interest in digital therapeutic interventions that reduce unnecessary healthcare utilisation are encouraging oncology digital therapeutic development. Strong digital health investment, established cancer patient advocacy infrastructure, and growing demand for between-visit care management are generating regional digital therapeutic oncology demand.
Highest CAGR Region
Europe is expected to register the highest CAGR of 20.31% during the forecast period. Oncology digital therapeutic companies, academic cancer research institutions, and health technology organisations across Germany, France, the United Kingdom, and the Nordic countries are developing digital therapeutic programmes for cancer patient symptom management and quality of life. European Medicines Agency digital therapeutic regulatory frameworks and growing national health system interest in evidence-based digital health interventions for oncology are encouraging platform development. Rising demand for patient-centred cancer care models and increasing interest in remote symptom monitoring are generating European oncology digital therapeutic adoption.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Digital Therapeutics Oncology Market was valued at USD 2.39 Bn in 2025 and is projected to reach USD 9.98 Bn by 2034, growing at a CAGR of 17.2% over the 2026–2034 forecast period.
The Digital Therapeutics Oncology Market is projected to grow at a CAGR of 17.2% from 2026 to 2034.
North America accounted for the largest share of the Digital Therapeutics Oncology Market in 2025, holding 53.8% of the global market.
The leading companies in the Digital Therapeutics Oncology Market include Swing Therapeutics (Rejoyn), Liminal Sciences, Mahana Therapeutics, Headspace Health (Oncology), Kaia Health (Cancer), Lucid Lane, Canopy Cancer Care, OncoPower, TailorMed, WellSheet.
Pear therapeutics and swing therapeutics advance prescription digital therapeutics for cancer symptom management.
By indication, the Cancer-Related Insomnia Management segment dominated the Digital Therapeutics Oncology Market in 2025.
How to Order
Choose Your Package
Condensed edition of this study for students, researchers and academic institutions.
- Condensed edition of the full study
- For students, researchers & academic institutions
- Valid student ID or institutional email required
- Educational, non-commercial use only
The competitive landscape, including key market participants, company size, market positioning, and comparative competitive standing.
- 15 in-depth company profiles
- Company overview
- Product and brand portfolio mapped per company
- Revenue for the last 3 FYs with key financial metrics
- Segmental revenue and regional revenue breakdown
- Market presence, key geographies & end-use industries
- Recent developments
- Key capabilities, differentiators & strategic positioning
- SWOT Analysis
- 15-company market share analysis
- 2025 market share by company
- Company revenue in USD
- Competitive quadrant positioning
- Product portfolio comparison
The complete forecast model, including every study table, is provided in clean, formula-ready Excel format across 3 segmentation axes. Select the geographic coverage required for your analysis.
- One country, broken out across 3 segmentation axes
- 2025 base year, 2026–2034 forecast, CAGR per line
- Excel workbook
- Region totals plus every country inside that region
- All axes, all years, CAGR per line
- Cross-country comparison sheet included
- Excel workbook
- Every forecast table in the study
- Global, regional and country views in one workbook
- Segment share and CAGR pivots included
- Excel workbook
The full syndicated study. Every chapter, every region, every country, plus the complete Excel model, methodology and appendix.
- Executive summary, market scope & segmental snapshot
- Market dynamics: drivers, restraints, opportunities, challenges
- Quantitative analysis across 3 segmentation axes
- Regional analysis
- Competitive landscape, market share & company revenue mapping
- Includes the full Global Excel Data Pack
- Complete research methodology, assumptions & appendix
TAM/SAM/SOM sizing, M&A target screening, patent & IP analysis, supply-chain resilience mapping, ESG roadmaps and other bespoke strategic work.
- TAM / SAM / SOM sizing
- M&A target screening
- Patent & IP analysis
- Supply-chain resilience mapping
- ESG roadmaps & other bespoke strategic work
Not sure which package fits? Tell us the decision you are making and an analyst will recommend the smallest package that answers it. Talk to an analyst.
Ordering Process
Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.